Publications
Detailed Information
MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gerds, Aaron | - |
dc.contributor.author | Verstovsek, Srdan | - |
dc.contributor.author | Vannucchi, Alessandro | - |
dc.contributor.author | Al-Ali, Haifa Kathrin | - |
dc.contributor.author | Lavie, David | - |
dc.contributor.author | Kuykendall, Andrew | - |
dc.contributor.author | Grosicki, Sebastian | - |
dc.contributor.author | Iurlo, Alessandra | - |
dc.contributor.author | Goh, Yeow Tee | - |
dc.contributor.author | Lazaroiu, Mihaela | - |
dc.contributor.author | Egyed, Miklos | - |
dc.contributor.author | Fox, Maria Laura | - |
dc.contributor.author | McLornan, Donal | - |
dc.contributor.author | Perkins, Andrew | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Gupta, Vikas | - |
dc.contributor.author | Kiladjian, Jean-Jacques | - |
dc.contributor.author | Donahue, Rafe | - |
dc.contributor.author | Kawashima, Jun | - |
dc.contributor.author | Mesa, Ruben | - |
dc.date.accessioned | 2022-10-17T04:16:44Z | - |
dc.date.available | 2022-10-17T04:16:44Z | - |
dc.date.created | 2022-10-14 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.citation | Clinical Lymphoma, Myeloma and Leukemia, Vol.22, p. S340 | - |
dc.identifier.issn | 2152-2650 | - |
dc.identifier.uri | https://hdl.handle.net/10371/186146 | - |
dc.description.abstract | © 2022 Elsevier Inc.Background: MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, was evaluated (vs DAN) in a pivotal phase 3 study of MF patients previously treated with a JAK inhibitor (JAKi). This subgroup analysis evaluated MOMENTUM patients with baseline platelet counts ≤150 × 109/L. Methods: Eligibility: Primary or post-ET/PV MF; DIPSS high risk, Int-2, or Int-1; total symptom score (TSS) ≥10; hemoglobin <10 g/dL; prior JAKi ≥90 days, or ≥28 days if RBC transfusions ≥4 units in 8 weeks or Grade 3/4 thrombocytopenia, anemia, or hematoma; palpable spleen ≥5 cm; platelets ≥25 × 109/L. JAKi taper/washout ≥21 days. Randomization 2:1 to MMB 200 mg or DAN 600 mg QD (+ placebo) for 24 weeks. Primary endpoint: TSS response (≥50% reduction from baseline) rate at week 24. Secondary endpoints at week 24: transfusion independence (TI) rate, splenic response rate (SRR; ≥25% volume reduction from baseline), TSS change from baseline, SRR (≥35% reduction), and rate of zero transfusions since baseline. Results: Mean baseline TSS: 29 MMB, 26 DAN, hemoglobin: 8.1 MMB, 7.8 DAN g/dL, and platelets: 74 × 109/L MMB, 73 × 109/L DAN. Efficacy results are consistent with the ITT analysis set for MMB vs DAN, respectively: TSS response rate (29.6% vs 11.6%), TI rate (32.1% vs 18.6%), SRR ≥25% (39.5% vs 7.0%), TSS change (-10.7 vs -3.8), SRR ≥35% (22.2% vs 4.7%), and rate of zero transfusions (30.9% vs 11.6%). Most common grade ≥3 TEAEs were thrombocytopenia (MMB, 31%; DAN, 16%) and anemia (MMB, 7%; DAN, 14%); grade ≥3 bleeding events: 9% MMB, 5% DAN. TEAEs leading to study drug discontinuation: 15% MMB, 19% DAN. A trend toward improved overall survival up to week 24 was seen with MMB vs DAN [HR (95% CI)=0.490 (0.195, 1.235)]. Analyses of patients with baseline platelets <100 × 109/L (N=100) and baseline platelets <50 × 109/L (N=31) show similar efficacy, safety, and survival profiles for MMB vs DAN. Conclusions: In symptomatic, anemic, and thrombocytopenic MF patients, MMB was superior to DAN for symptom responses, transfusion requirements, and spleen responses with comparable safety and favorable survival. MMB may address a critical unmet need in thrombocytopenic MF patients. NCT04173494. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier Inc. | - |
dc.title | MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/S2152-2650(22)01464-1 | - |
dc.citation.journaltitle | Clinical Lymphoma, Myeloma and Leukemia | - |
dc.identifier.scopusid | 2-s2.0-85138143484 | - |
dc.citation.startpage | S340 | - |
dc.citation.volume | 22 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Yoon, Sung-Soo | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.